Current Therapeutic Sequencing in Chronic Lymphocytic Leukemia
Hematology Reports · 30.04.2024 · 16 (2) · 270-282
DOI: 10.3390/hematolrep16020027 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Hematology Reports, online erschienen am 30.04.2024. Verfasst von Samir Mouhssine und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Department of Translational Medicine, Università del Piemonte Orientale and Azienda Ospedaliero-Universitaria Maggiore della …. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The treatment landscape of chronic lymphocytic leukemia (CLL), the most frequent leukemia in adults, is constantly changing. CLL patients can be divided into three risk categories, based on their IGHV mutational status and the occurrence of TP53 disruption and/or complex karyotype. For the first-line treatment of low- and intermediate-risk CLL, both the BCL2 inhibitor venetoclax plus obinutuzumab and the second generation BTK inhibitors (BTKi), namely acalabrutinib and zanubrutinib, are valuable and effective options. Conversely, venetoclax-based fixed duration therapies have not shown remarkable results in high-risk CLL patients, while continuous treatment with acalabrutinib and zanubrutinib displayed favorable outcomes, similar to those obtained in TP53 wild-type patients. The development of acquired resistance to pathway inhibitors is still a clinical challenge, and the optimal treatment sequencing of relapsed/refractory CLL is not completely established. Covalent BTKi-refractory patients should be treated with venetoclax plus rituximab, whereas venetoclax-refractory CLL may be treated with second generation BTKi in the case of early relapse, while venetoclax plus rituximab might be used if late relapse has occurred. On these grounds, here we provide an overview of the current state-of-the-art therapeutic algorithms for treatment-naïve patients, as well as for relapsed/refractory disease.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Hematology, Department of Translational Medicine, Università del Piemonte Orientale and Azienda Ospedaliero-Universitaria Maggiore della Carità, 28100 Novara, Italy.
- Hematology Unit, Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"-IRST IRCCS, 47014 Meldola, Italy.
- Department of Hematology and Sciences Oncology, Institute of Haematology "L. and A. Seràgnoli", S. Orsola University Hospital, 40138 Bologna, Italy.
ORCID-Profile: Samir Mouhssine, Nawar Maher, Claudio Cerchione, Giovanni Martinelli, Gianluca Gaidano
Zitieren
APA
Mouhssine, S., Maher, N., Kogila, S., Cerchione, C., Martinelli, G., & Gaidano, G. (2024). Current Therapeutic Sequencing in Chronic Lymphocytic Leukemia. Hematology Reports, 16(2), 270-282. https://doi.org/10.3390/hematolrep16020027
Vancouver
Mouhssine S, Maher N, Kogila S, Cerchione C, Martinelli G, Gaidano G. Current Therapeutic Sequencing in Chronic Lymphocytic Leukemia. Hematology Reports. 2024;16(2):270-282. doi:10.3390/hematolrep16020027
BibTeX
@article{Mouhssine2024,
author = {Mouhssine, Samir and Maher, Nawar and Kogila, Sreekar and Cerchione, Claudio and Martinelli, Giovanni and Gaidano, Gianluca},
title = {Current Therapeutic Sequencing in Chronic Lymphocytic Leukemia},
journal = {Hematology Reports},
year = {2024},
volume = {16},
number = {2},
pages = {270--282},
doi = {10.3390/hematolrep16020027}
}
EUVIMED